AU2019384523B2 - Split interleukin mimetics and their use - Google Patents

Split interleukin mimetics and their use

Info

Publication number
AU2019384523B2
AU2019384523B2 AU2019384523A AU2019384523A AU2019384523B2 AU 2019384523 B2 AU2019384523 B2 AU 2019384523B2 AU 2019384523 A AU2019384523 A AU 2019384523A AU 2019384523 A AU2019384523 A AU 2019384523A AU 2019384523 B2 AU2019384523 B2 AU 2019384523B2
Authority
AU
Australia
Prior art keywords
seq
polypeptide
amino acid
peptide
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019384523A
Other languages
English (en)
Other versions
AU2019384523A1 (en
Inventor
David Baker
Marc Joseph LAJOIE
Alfredo QUIJANO RUBIO
Daniel Adriano SILVA MANZANO
Umut ULGE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington filed Critical University of Washington
Publication of AU2019384523A1 publication Critical patent/AU2019384523A1/en
Application granted granted Critical
Publication of AU2019384523B2 publication Critical patent/AU2019384523B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2019384523A 2018-11-20 2019-11-19 Split interleukin mimetics and their use Active AU2019384523B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862770152P 2018-11-20 2018-11-20
US62/770,152 2018-11-20
PCT/US2019/062198 WO2020106708A1 (en) 2018-11-20 2019-11-19 Split interleukin mimetics and their use

Publications (2)

Publication Number Publication Date
AU2019384523A1 AU2019384523A1 (en) 2021-04-22
AU2019384523B2 true AU2019384523B2 (en) 2025-08-28

Family

ID=69500815

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019384523A Active AU2019384523B2 (en) 2018-11-20 2019-11-19 Split interleukin mimetics and their use

Country Status (13)

Country Link
US (2) US12234572B2 (https=)
EP (1) EP3883956A1 (https=)
JP (2) JP2022511390A (https=)
KR (1) KR20210094531A (https=)
CN (2) CN112912388A (https=)
AU (1) AU2019384523B2 (https=)
BR (1) BR112021008985A2 (https=)
CA (1) CA3119472A1 (https=)
EA (1) EA202190593A1 (https=)
IL (1) IL283217A (https=)
MX (1) MX2021005593A (https=)
SG (1) SG11202103045SA (https=)
WO (1) WO2020106708A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP3810640A1 (en) * 2018-06-25 2021-04-28 University of Washington De novo design of potent and selective interleukin mimetics
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
EP3883956A1 (en) 2018-11-20 2021-09-29 University of Washington Split interleukin mimetics and their use
JP7710373B2 (ja) 2019-02-21 2025-07-18 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
EP4288548A4 (en) * 2021-02-05 2025-01-15 Dharmacon, Inc. FUSION PROTEINS FOR CRISPR-BASED TRANSCRIPTION REPRESSION
WO2023044318A2 (en) * 2021-09-15 2023-03-23 Neoleukin Therapeutics, Inc. Interleukin-2 receptor βeta (il-2rβ) binding polypeptides
CN118715024A (zh) * 2022-01-24 2024-09-27 诺夫免疫股份有限公司 用于细胞因子信号传导通路的选择性激活的组合物和方法
IL322524A (en) 2023-03-07 2025-10-01 Chugai Pharmaceutical Co Ltd Conditional receptor signaling via scaffolding protein
EP4722235A1 (en) * 2023-05-24 2026-04-08 Nantong Yichen Biopharma. Co. Ltd. Polypeptide, and conjugate and use thereof
TW202519542A (zh) * 2023-07-13 2025-05-16 美商奧特佩斯生化股份有限公司 經設計之細胞激素組合物及使用方法
WO2025212606A1 (en) * 2024-04-01 2025-10-09 Bio-Techne Corporation Synthetic il-2 polypeptides and conjugates, compositions, and uses thereof
WO2026039791A1 (en) * 2024-08-16 2026-02-19 Regeneron Pharmaceuticals, Inc. Tumor-targeted split il2 receptor agonists
WO2026078029A1 (en) * 2024-10-10 2026-04-16 F. Hoffmann-La Roche Ag Splitted interleukin-2 prodrugs and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012337A1 (en) * 2000-08-09 2002-02-14 European Molecular Biology Laboratory Peptide mimetics
WO2002101629A1 (en) * 2001-06-07 2002-12-19 Wyeth Solution structure of il-13 and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1015080A (en) 1908-04-17 1912-01-16 George I Rockwood Apparatus for operating alarms or other devices.
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
US6168785B1 (en) 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
CN1930300A (zh) * 2004-03-05 2007-03-14 希龙公司 预测患者治疗药物耐受性的体外试验系统
US20110020269A1 (en) 2007-05-08 2011-01-27 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for modifying t cell immune responses and inflammation
US9676871B2 (en) 2010-11-05 2017-06-13 Pfizer Inc. Engineered polypeptide conjugates and methods for making thereof using transglutaminase
US9428567B2 (en) 2010-12-22 2016-08-30 The Board Of Trustees Of The Leland Stanford Junior University Antagonists of interleukin-2 receptor
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
WO2015164815A1 (en) 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
US9777070B2 (en) 2014-04-30 2017-10-03 Pfizer Inc Anti-PTK7 antibody-drug conjugates
WO2016025385A1 (en) 2014-08-11 2016-02-18 Delinia, Inc. Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
WO2018153865A1 (en) 2017-02-24 2018-08-30 Philogen S.P.A. Immunoconjugates with optimized linkers and orientation
ES2894731T3 (es) 2017-03-15 2022-02-15 Silverback Therapeutics Inc Compuestos de benzazepina, conjugados y usos de los mismos
EP3810640A1 (en) 2018-06-25 2021-04-28 University of Washington De novo design of potent and selective interleukin mimetics
EP3883956A1 (en) 2018-11-20 2021-09-29 University of Washington Split interleukin mimetics and their use
EP3883585A4 (en) 2018-11-20 2022-12-14 Innovative Cellular Therapeutics Holdings, Ltd. MODIFIED CELL EXPRESSING THERAPEUTIC AND USES THEREOF
JP2022553370A (ja) 2019-10-25 2022-12-22 ネオルーキン セラピューティクス，インコーポレイティド Ｉｌ－２受容体作動薬の投与方法
US20230331858A1 (en) 2019-12-24 2023-10-19 Neoleukin Therapeutics, Inc. Combination therapy using an il-2 receptor agonist and an immune checkpoint inhibitor
CN111040981A (zh) 2019-12-26 2020-04-21 南昌大学 表达重组IL-2的重组大肠杆菌Nissle 1917及其功能验证方法
EP4121449A2 (en) 2020-03-16 2023-01-25 Neoleukin Therapeutics, Inc. Interleukin-2 receptor beta (il-2rb) binding polypeptides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012337A1 (en) * 2000-08-09 2002-02-14 European Molecular Biology Laboratory Peptide mimetics
WO2002101629A1 (en) * 2001-06-07 2002-12-19 Wyeth Solution structure of il-13 and uses thereof

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AARON CHEVALIER ET AL "Massively parallel de nova protein design for targeted therapeutics" NATURE (2017) 550: 74-79 *
DOMINGUES H ET AL "RATIONAL DESIGN OF A GCN4-DERIVED MIMETIC OF INTERLEUKIN-4" NATURE STRUCTURAL BIOLOGY (1999) 6: 652-656 *
GLORIA RUIZ-GOMEZ ET AL "Rational Structure-Based Rescaffolding Approach to De Novo Design of Interleukin 10 (IL-10) Receptor-1 Mimetics" PLOS ONE (2016) 11: e0154046 *
RAKEEB KURESHI ET AL "Reprogramming immune proteins as therapeutics using molecular engineering" CURRENT OPINION IN CHEMICAL ENGINEERING (2017) 19: 27-34 *
RALPH ECKENBERG ET AL "IL-2R[beta] Agonist P1-30 Acts in Synergy with IL-2, IL-4, IL-9, and IL-15: Biological and Molecular Effects" THE JOURNAL OF IMMUNOLOGY (2000) 165: 4312-4318 *
S. E. BOYKEN ET AL "De nova design of protein homo-oligomers with modular hydrogen-bond network-mediated specificity" SCIENCE (2016) 352: 680-687 *
SUMAN MITRA ET AL "lnterleukin-2 Activity Can Be Fine Tuned with Engineered Receptor Signaling Clamps" IMMUNITY (2015) 42: 826-838 *

Also Published As

Publication number Publication date
US12234572B2 (en) 2025-02-25
IL283217A (en) 2021-06-30
CN120040576A (zh) 2025-05-27
CN112912388A (zh) 2021-06-04
US20220017588A1 (en) 2022-01-20
BR112021008985A2 (pt) 2021-10-26
AU2019384523A1 (en) 2021-04-22
SG11202103045SA (en) 2021-04-29
WO2020106708A1 (en) 2020-05-28
US20250179690A1 (en) 2025-06-05
EP3883956A1 (en) 2021-09-29
CA3119472A1 (en) 2020-05-28
MX2021005593A (es) 2021-08-11
JP2022511390A (ja) 2022-01-31
KR20210094531A (ko) 2021-07-29
EA202190593A1 (ru) 2021-11-18
JP2025013348A (ja) 2025-01-24

Similar Documents

Publication Publication Date Title
AU2019384523B2 (en) Split interleukin mimetics and their use
US12240880B2 (en) De novo design of potent and selective interleukin mimetics
EP4083073B1 (en) Novel chimeric antigen receptor and use thereof
CN106459219B (zh) 白细胞介素15蛋白复合物及其用途
US10280425B2 (en) Minicircle DNA recombinant parental plasmid having genetically engineered antibody gene expression cassette, a minicircle DNA having the expression cassette, and applications
US20170252435A1 (en) Combination
WO2024148369A1 (en) Targeted il-12 affinity variants
WO2019129143A1 (zh) 靶向ErbB受体家族的嵌合抗原受体修饰T细胞及其用途
HK1231090B (zh) 白细胞介素15蛋白复合物及其用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)